Cancer News
OncoLink Cancer News - HealthDay


FDA: Pomalyst Approved for Advanced Multiple Myeloma

Monday, February 11, 2013 (Last Updated: 02/12/2013)

MONDAY, Feb. 11 (HealthDay News) -- Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.

Multiple myeloma affects some 21,700 Americans annually and nearly 10,700 die from it each year, the agency said Friday in a news release.

Pomalyst is designed to spur the immune system to destroy and inhibit cancer cells, the FDA said. The drug's safety and effectiveness were evaluated in a clinical study of 221 people with advanced multiple myeloma.

The drug's label will contain a boxed warning that it shouldn't be used by pregnant women since it can cause life-threatening birth defects and blood clots, the FDA said.

More common side effects could include neutropenia, fatigue, weakness, other blood disorders, back pain, and fever.

The drug is marketed by Celgene, based in Summit, N.J.

More Information

Specialties Hematology & Oncology
Urology
Nursing
Family Practice
Internal Medicine
Geriatrics

Copyright © 2013 HealthDay. All rights reserved.


I Wish You Knew

What it takes to be an oncology nurse

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More